Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma

Journal of Infectious Diseases

Volumn 203, Issue 8, 2011, Pages 1082-1086

  Krown, Susan E ^a   Dittmer, Dirk P ^b   Cesarman, Ethel ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; KAPOSI SARCOMA ASSOCIATED HERPESVIRUS ANTIGEN; LATENCY ASSOCIATED NUCLEAR ANTIGEN; OPEN READING FRAME 59 PROTEIN; OPEN READING FRAME K8.1 PROTEIN; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN TISSUE; KAPOSI SARCOMA; KIDNEY FUNCTION; MALE; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; TUMOR BIOPSY; TUMOR GROWTH;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; GANCICLOVIR; HERPESVIRUS 8, HUMAN; HUMANS; MIDDLE AGED; SARCOMA, KAPOSI;

EID: 79953302391     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq177     Document Type: Article

References (15)

1. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in KS in patients with and without HIV infection. N Engl J Med 1995; 332:1181-5.
2. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's Sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86:1276-80.
3. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186-91.
4. Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 2010; 120:939-49.
5. Medveczky MM, Horvath E, Lund T, Medveczky PG. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 1997; 11:1327-2.
6. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99:2082-6. (Pubitemid 27203763)
7. Jones JL, Hanson DL, Dworkin MS, Jaffe HW. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 24:270-4.
8. Morfeldt L, Torssander J. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis 1994; 26:749-52.
9. Robles R, Lugo D, Gee L, Jacobson MA. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:34-8. (Pubitemid 29045467)
10. Cordero E, Lopez-Cortes LF, Viciana P, Alarcon A, Pachon J. Foscarnet and AIDS-associated Kaposi's sarcoma. AIDS 1997; 11:1787-8.
11. Little RF, Merced-Galindez F, Staskus K, et al. A pilot study of cidofovir in patients with Kaposi sarcoma. J Infect Dis 2003; 187:149-53. (Pubitemid 36034485)
12. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002; 20:153-9. (Pubitemid 34032606)
13. Dittmer DP. Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by realtime PCR arrays. Cancer Res 2003; 63:2010-5. (Pubitemid 36538598)
14. Casper C, Krantz E, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008; 198:23-30. (Pubitemid 351920285)
15. Phipps W, Orem J, Mutyaba I, et al. Characterization of lytic human herpesvirus-8 gene expression in Kaposi sarcoma tumor tissue and its clinical correlates. [abstract 4] 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI). Bethesda, MD: 2010:66.